ArticleBritish journal of clinical pharmacology2026
Oseltamivir drug-disease modelling in infants with influenza virus infection.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oseltamivir drug-disease modelling in infants with influenza virus infection.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsOseltamivir is a commonly used neuraminidase inhibitor for treatment of influenza infection, but little data exist regarding concentration-response relationships.
methodsPharmacokinetic (PK) and viral dynamic data from an earlier NIAID Collaborative Antiviral Study Group trial in paediatric patients with influenza from 0-23 months of age were used to create a PK model linked to an influenza viral dynamic model. Population PK parameters were used to perform broad dose-ranging simulations to determine the oseltamivir carboxylate exposure required to achieve 95% of maximum viral suppression (EC
resultsA total of 373 plasma samples for oseltamivir and 382 plasma samples for oseltamivir carboxylate from 78 infants were included. The median age and weight at the time of PK sampling were 8 months and 8 kg, respectively. Sixty-two babies with measured influenza viral loads over the course of treatment (12 days, n = 239) were included in the viral dynamic modelling. The modelled EC
conclusionsPopulation pharmacokinetic modelling can be directly linked to viral dynamic outcomes and through simulations, dose-ranging studies performed to identify target drug exposures. This approach could be used as a surrogate when concentration-response data do not exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.